Abstract Library

#4217 Prediction of recurrence for grade 1-2 small bowel neuroendocrine neoplasms after curative-intended resection

Introduction: In patients with grade 1 to 2 small bowel neuroendocrine neoplasms (SB-NEN) reccurrence rates are reported up to 50%. No prediction tools exist yet to identify patients at high-risk for recurrence in SB-NENs.

Conference:

Presenting Author:

Authors: Erdmann F, Addeo P, Falconi M, Hennings J, Makay �,

Keywords: small bowel neuroendocrine neoplasm, recurrence, nomogram,

#4158 Transcriptomic analysis of PanNET tumor progression from microtumor to metastasis in MEN1 patients

Introduction: Pancreatic Neuroendocrine Neoplasms (PanNENs) are a major component the Multiple Endocrine Neoplasia 1 Syndrome (MEN1). Although multiple pancreatic neuroendocrine microtumors (microadenomatosis) are a histomorphological hallmark of MEN1, their molecular status compared to PanNET as well as their metastasis remains unclear.

Conference:

Presenting Author:

Authors: Chouchane A, Kirchner P, Sylvain Maire R, Schiavo Lena M, Falconi M,

Keywords: Microtumor, MEN1, PanNETs, RNAseq, Transcriptomics, Progression,

#3882 Adjuvant therapy for pancreatic neuroendocrine tumors – Expert consensus and recommendations for future research

Introduction: With the increase of incidentally diagnosed pancreatic neuroendocrine tumors (panNEN), more patients are treated with curative intent. Survival in patients with a panNEN is impacted by the development of recurrence, but postoperative adjuvant therapy is not yet recommended in guidelines due to absence of evidence. Multiple clinicopathological characteristics have been described in literature to identify patients at high-risk of recurrence who might benefit from adjuvant treatment. Since panNEN are rare tumors, prospective randomized controlled studies on the role of adjuvant therapy in these patients have not been performed.

Conference:

Presenting Author: Heidsma C

Authors: Heidsma C, Engelsman A, Klümpen H, Falconi M, Frilling A,

Keywords: pancreatic neuroendocrine tumor, recurrence, adjuvant therapy, prevention, expert consensus, future research,

#2276 Ki-67 to Predict Recurrence and Survival of Pancreatic Neuroendocrine Tumors

Introduction: Despite evidence of different malignant potential, postoperative follow-up is similar for G1 and G2 pancreatic neuroendocrine tumors (panNET) and adjuvant treatment is currently not indicated.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Genc C, Falconi M, Partelli S, Muffatti F, Van Eeden S,

Keywords: Neuroendocrine tumors, pancreas, recurrence, survival, Ki-67 proliferation index, prognosis,

#1677 A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Non-Functional Pancreatic Neuroendocrine Tumors.

Introduction: Surgical resection is the preferred treatment for NF-pNET, however recurrence still occurs frequently after curative surgery, worsening prognosis of patients.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Genc C

Authors: Genc C, Jilesen A, Partelli S, Falconi M, Muffatti F,

Keywords: pNET, recurrence, predictive-model.,